Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

When Eli Lilly & Co. on Tuesday announced pricing and packaging changes for its popular weight-loss drug Zepbound, the drugmaker said it was expanding access for people living with obesity — but ...

In May, a similar 401(k) lawsuit was filed against Cigna in the same district court in Pennsylvania. In Reven et al. v.The Cigna Group 401(k) Plan Retirement Plan Committee, former employees accused ...

Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick with strong growth potential.

Dive Insight: Though Novo is a pioneer in the development of in-demand obesity medicines, it currently finds itself on the defensive.Zepbound’s fast launch has eroded Wegovy’s market share, and Novo’s ...

If HS-20094 becomes nearly as successful as Zepbound, the $80 million Regeneron paid -- and the $1.93 billion in milestones -- would represent quite the bargain. However, it is too early to celebrate.

Cigna Healthcare, the health benefits division of the Cigna Group, has released a set of digital tools aimed at improving the ...

By Amina Niasse (Reuters) -Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some analysts see a need for the online website to adjust ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some analysts see a need for the online website to adjust to changing competition in ...

Lilly Pacts Prohibit Telehealth Sales of Copycat Zepbound (1) June 10, 2025, 6:26 PM UTC. Madison Muller . Eli Lilly & Co. will only work with telehealth firms that agree to stop selling copycat ...

CVS Health and Cigna announced new strategies for weight-loss drugs, by limiting which it will cover or out-of-pocket costs. Leerink's Cherny said any expansion of insurance coverage for the drugs ...